Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis

Melissa Hallow, Karen; Helmlinger, Gabriel; J. Greasley, Peter; J.V. McMurray, John; W. Boulton, David

doi:10.1111/dom.13126

Public

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

Published in Diabetes Obesity and Metabolism • Oct 12, 2017

Authors:

Karen Melissa Hallow

Gabriel Helmlinger

Peter J. Greasley

Abstract

The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinct...

Subject

Medicine

Heart failure

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!